Home » Topics » Science » New compound

New compound
RSS

KV-998083 effective in models of thrombosis and vascular leakage

July 30, 2021

Ghent University Hybrid CAR-T cell platform has dual anti-HIV effects

July 28, 2021

CFT-2718 shows promising tumor growth reduction in models of SCLC

July 23, 2021

Discovery of novel siderophore-monobactam conjugates against P. Aeruginosa

July 15, 2021

TP-03 enhances the stimulating effect of hCG on testicular steroidogenesis

July 14, 2021

VRG-101: a new PIKfyve inhibitor for SARS-CoV-2

July 14, 2021

Pentadefenin hydrogel developed for treating vaginitis

July 12, 2021

EDP-721, a novel HBV RNA destabilizer with promising preclinical efficacy

July 9, 2021

Dual GIP/GLP-1 receptor agonist HISHS-2001 displays efficacy in type 2 diabetes model

July 8, 2021

New TGF-beta inhibitor KS-356 improves experimental obesity, hepatic steatosis

July 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...